Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study it to evaluate the safety and immune response of peptides (URLC10) emulsified with Montanide ISA51 in treating patients with unresectable, advanced or recurrent gastric cancer.

Detailed Description
-----------------
URLC10 has been identified as cancer specific molecules especially in non small cell lung cancer using genome-wide expression profile analysis by cDNA microarray technique. In a prior study, it has been shown that URLC10 are upregulated in esophageal cancer and gastric cancer and other cancer. The investigators identified that peptides derived from these proteins significantly induce the effective tumor specific CTL response in vitro. According to these findings, in this trial, the investigators evaluate the safety, immunological and clinical response of URLC10 peptide vaccine in the patients with gastric cancer. Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection

Official Title
-----------------
Tumor Vaccine Therapy Against Advanced Gastric Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Biological: peptide vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must have Advanced or recurrent gastric cancer, and treatment has failed, or in the situation where effective therapy is not available, or has been refused due to severe adverse effects of chemotherapy WHO performance status of 0 to 2 Age ≥ 20 years, ≤80 years The patient does not need to have a measurable disease, but must have a disease that an effect judgment is possible Passing from previous treatment more than two weeks. Expected survival of at least 3 months WBC≥ 1,500/mm³ WBC≤ 15,000/mm³ Platelet count ≥ 50,000/mm³ Total bilirubin≤ 3 x the institutional normal upper limits AST, ALT ≤ 3 x the institutional normal upper limits Creatinine ≤ 3 x the institutional normal upper limits Patients must be HLA-A2402 Able and willing to give valid written informed consent Exclusion Criteria: Pregnancy, Promise of the pregnancy, Hope of the pregnancy, Breastfeeding Serious infections requiring antibiotics Concurrent treatment with steroids or immunosuppressing agent Decision of unsuitableness by principal investigator or physician-in-charge

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: peptide vaccine|peptides emulsified with Montanide ISA51|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety(Phase I:toxicities as assessed by NCI CTCAE version3) |  | 28 days after beginning protocol | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| efficacy(Feasibility as evaluated by RECIST) |  | 28 days after beginning protocol | 
| evaluate immunological responses |  | 28 days after beginning protocol | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
peptide vaccine, URLC10